Anika Therapeutics Inc.
ANIK
Get informed when a big investor buys or sells
+ FollowMarket Cap$278.5M
Close$
$18.52
9.1% downside
Current Fair Value
9.1% downsideOvervalued by 9.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $278.50 Million |
|---|---|
| Enterprise Value | $263.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.76 |
| Beta | 0.2 |
| Outstanding Shares | 13,430,000 |
Return
| Return on Equity | -1.66% |
|---|---|
| Return on Assets | -1.24% |
| Return on Invested Capital | -0.85% |
Valuation & Multiples
| P/E Ratio | -77.22 |
|---|---|
| PEG | 42.11 |
| Price to Sales | 2.55 |
| Price to Book Ratio | 2.04 |
| Enterprise Value to Revenue | 2.18 |
| Enterprise Value to EBIT | -192.69 |
| Enterprise Value to Net Income | -116 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$29.21 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$29.44 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 91.97%▲ 0.63% |
|---|---|
| Total Invested | $181.28M▲ 1.24% |
| Investors Holding | 135▲ 4.00% |
ESG Score
No data
About Anika Therapeutics Inc.
CEO: Joseph Darling